Medical Publications
The publicationsResponseSchema is this .json,
PublicationsResponseSchema
{
"year": "string",
"abstract": "string",
"authors": [...],
"classification": [...],
"free_category_name": "string",
"highlights": "string",
"id": "string",
"source": "string",
"title": "string",
"urls": [...]
}
Field free_category_name contains indication of open source articles from Pubmed Central, only avalible whithin Pubmed source.
Field urls contains, when available, the links to the abstract of the article in Pubmed and to the original end source.
This is a example to response with pubmed and query T Cell Therapy in Lymphoma.
Example with Pubmed with te query=
{
"Pubmed"{
"0": {"id": "33846220", "year": "2021",…},
"abstract": "Chimeric antigen receptor (CAR) T-cell therapies that specifically target the CD19 antigen have emerged as a highly effective treatment option in patients with refractory B-cell hematological malignancies. Safety and efficacy outcomes from the pivotal prospective clinical trials of axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel and the retrospective, postmarketing, real-world analyses have confirmed high response rates and durable remissions in patients who had failed multiple lines of therapy and had no meaningful treatment options. Although initially administered in the inpatient setting, there has been a growing interest in delivering CAR-T cell therapy in the outpatient setting; however, this has not been adopted as standard clinical practice for multiple reasons, including logistic and reimbursement issues. CAR-T cell therapy requires a multidisciplinary approach and coordination, particularly if given in an outpatient setting. The ability to monitor patients closely is necessary and proper protocols must be established to respond to clinical changes to ensure efficient, effective and rapid evaluation either in the clinic or emergency department for management decisions regarding fever, sepsis, cytokine release syndrome and neurological events, specifically immune effector cell-associated neurotoxicity syndrome. This review presents the authors' institutional experience with the preparation and delivery of outpatient CD19-directed CAR-T cell therapy.",
"authors": [
"Myers GD",
"Verneris MR",
"Goy A",
"Maziarz RT"]
"classification": [
"Journal Article",
"Research Support, Non-U.S. Gov't",
"Review"]
"free_category_name": "Free PMC article.",
"highlights": "",
"id": "33846220",
"source": "National Center for Biotechnology Information (NCBI)[Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [1988] - [cited 2022 Sep 26]. Available from: https://www.ncbi.nlm.nih.gov/",
"title": "Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia.",
"urls": [{"type": "pubmed", "copy": "PUBMED", "url": "https://www.ncbi.nlm.nih.gov/pubmed/33846220"},…],
"year": "2021",
"1": {"id": "34248965", "year": "2021",…},
"abstract": "Non-Hodgkin's lymphoma (NHL) is a cancer that starts in the lymphatic system. In NHL, the important part of the immune system, a type of white blood cells called lymphocytes become cancerous. NHL subtypes include marginal zone lymphoma, small lymphocytic lymphoma, follicular lymphoma (FL), and lymphoplasmacytic lymphoma. The disease can emerge in either aggressive or indolent form. 5-year survival duration after diagnosis is poor among patients with aggressive/relapsing form of NHL. Therefore, it is necessary to understand the molecular mechanisms of pathogenesis involved in NHL establishment and progression. In the next step, we can develop innovative therapies for NHL based on our knowledge in signaling pathways, surface antigens, and tumor milieu of NHL. In the recent few decades, several treatment solutions of NHL mainly based on targeted/directed therapies have been evaluated. These approaches include B-cell receptor (BCR) signaling inhibitors, immunomodulatory agents, monoclonal antibodies (mAbs), epigenetic modulators, Bcl-2 inhibitors, checkpoint inhibitors, and T-cell therapy. In recent years, methods based on T cell immunotherapy have been considered as a novel promising anti-cancer strategy in the treatment of various types of cancers, and particularly in blood cancers. These methods could significantly increase the capacity of the immune system to induce durable anti-cancer responses in patients with chemotherapy-resistant lymphoma. One of the promising therapy methods involved in the triumph of immunotherapy is the chimeric antigen receptor (CAR) T cells with dramatically improved killing activity against tumor cells. The CAR-T cell-based anti-cancer therapy targeting a pan-B-cell marker, CD19 is recently approved by the US Food and Drug Administration (FDA) for the treatment of chemotherapy-resistant B-cell NHL. In this review, we will discuss the structure, molecular mechanisms, results of clinical trials, and the toxicity of CAR-T cell-based therapies. Also, we will criticize the clinical aspects, the treatment considerations, and the challenges and possible drawbacks of the application of CAR-T cells in the treatment of NHL.",
"authors": [
"Marofi F",
"Rahman HS",
"Achmad MH",
"Sergeevna KN",
"Suksatan W",
"Abdelbasset WK",
"Mikhailova MV",
"Shomali N",
"Yazdanifar M",
"Hassanzadeh A",
"Ahmadi M",
"Motavalli R",
"Pathak Y",
"Izadi S",
"Jarahian M"],
"classification": [,
"Journal Article",
"Research Support, Non-U.S. Gov't",
"Review"],
"free_category_name": "Free PMC article.",
"highlights": "",
"id": "34248965",
"source": "National Center for Biotechnology Information (NCBI)[Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [1988] - [cited 2022 Sep 26]. Available from: https://www.ncbi.nlm.nih.gov/",
"title": "A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.",
"urls": [{"type": "pubmed", "copy": "PUBMED", "url": "https://www.ncbi.nlm.nih.gov/pubmed/34248965"},…],
"year": "2021"
}
}